BR0313651A2 - composiÇço para administraÇço oral ou rectal - Google Patents

composiÇço para administraÇço oral ou rectal

Info

Publication number
BR0313651A2
BR0313651A2 BRPI0313651-5A BR0313651A BR0313651A2 BR 0313651 A2 BR0313651 A2 BR 0313651A2 BR 0313651 A BR0313651 A BR 0313651A BR 0313651 A2 BR0313651 A2 BR 0313651A2
Authority
BR
Brazil
Prior art keywords
composition
suppository
tablet
oral
rectal administration
Prior art date
Application number
BRPI0313651-5A
Other languages
English (en)
Inventor
Bengt Hersloef
Original Assignee
Ltp Lipid Technologies Provider Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltp Lipid Technologies Provider Ab filed Critical Ltp Lipid Technologies Provider Ab
Publication of BR0313651A2 publication Critical patent/BR0313651A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

COMPOSIÇçO PARA ADMINISTRAÇçO ORAL OU RECTAL. Uma composição sólida farmacêutica ou de suplemento alimentar para comprimido ou supositório tem um ponto de fusão de 250C ou superior e compreende um componente lipídíco continuo compreendendo um ou mais lípidos polares, um ou mais lípidos não polares, opcionalmente um ou vários de água e álcool mono- a trívalente numa quantidade até 15% em peso da composição, e um ou mais agentes seleccionados de agente farmacologícamente activo e agente suplemento alimentar. Também é descrito um correspondente comprimido e um correspondente supositório, processos para a produção da composição e do comprimido e do supositório, e um método de tratamento de patologias susceptíveis de tratamento preventivo ou terapêutico por administração do comprimido ou supositório.
BRPI0313651-5A 2002-02-15 2003-02-14 composiÇço para administraÇço oral ou rectal BR0313651A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200475A SE0200475D0 (sv) 2002-02-15 2002-02-15 Oral farmaceutisk beredning
PCT/SE2003/000251 WO2003068267A1 (en) 2002-02-15 2003-02-14 Composition for oral or rectal administration

Publications (1)

Publication Number Publication Date
BR0313651A2 true BR0313651A2 (pt) 2008-11-11

Family

ID=20286999

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313651-5A BR0313651A2 (pt) 2002-02-15 2003-02-14 composiÇço para administraÇço oral ou rectal

Country Status (20)

Country Link
US (1) US20050181042A1 (pt)
EP (1) EP1474174B1 (pt)
JP (1) JP2005520816A (pt)
KR (1) KR20040089633A (pt)
CN (1) CN101060862A (pt)
AT (1) ATE430585T1 (pt)
AU (1) AU2003206355B2 (pt)
BR (1) BR0313651A2 (pt)
CA (1) CA2475025C (pt)
DE (1) DE60327511D1 (pt)
DK (1) DK1474174T3 (pt)
ES (1) ES2324603T3 (pt)
MX (1) MXPA04007946A (pt)
NZ (1) NZ534812A (pt)
PT (1) PT1474174E (pt)
RU (1) RU2302260C2 (pt)
SE (1) SE0200475D0 (pt)
SI (1) SI1474174T1 (pt)
WO (1) WO2003068267A1 (pt)
ZA (1) ZA200406399B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
SE0400233D0 (sv) * 2004-02-04 2004-02-04 Ltp Lipid Technologies Provide Rektal komposition
AU2006240551A1 (en) * 2005-04-28 2006-11-02 Dsm Ip Assets B.V. Pharmaceutical dosage forms comprising a lipid phase
WO2007098446A2 (en) * 2006-02-21 2007-08-30 Accu-Break Pharmaceuticals, Inc. Method for minimizing variation in dosage forms
CN101278928B (zh) 2007-04-06 2011-09-07 常州高新技术产业开发区三维工业技术研究所有限公司 含左卡尼汀或其衍生物的药物组合物及其用途
CN101991557B (zh) * 2009-08-10 2013-09-18 杭州赛利药物研究所有限公司 一种盐酸万古霉素液体胶囊及其制备方法
EP2699267A4 (en) * 2011-04-18 2014-11-12 Lipidor Ab LIQUID CARRIER FOR THE ORAL DELIVERY OF A PHARMACOLOGICAL ACTIVE SUBSTANCE
US10117885B2 (en) * 2011-08-11 2018-11-06 Allergy Research Group, Llc Chewable lipid supplements for treating pain and fibromyalgia
CN102631290A (zh) * 2012-04-05 2012-08-15 韩昌志 一种生产栓剂的综合法
US10456327B2 (en) 2015-08-28 2019-10-29 Craig Robertson Package for frozen nutrient pill

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7812466A (nl) * 1978-12-22 1980-06-24 Shell Int Research Werkwijze voor de bereiding van gasmengsels.
DE2951142C2 (de) * 1979-12-19 1983-11-03 A. Nattermann & Cie GmbH, 5000 Köln Suppositorium-Zubereitung von Indometacin oder Acemetacin
US4966776A (en) * 1983-04-11 1990-10-30 Board Of Regents, The University Of Texas System Compositions and methods of treating calcium renal stones
US4699776A (en) * 1985-06-28 1987-10-13 R. P. Scherer Corporation Suppositories containing analgesics, antipyretics or anti-inflammatory agents
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
NZ231281A (en) * 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
SE9003100D0 (sv) * 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
CA2146999A1 (en) * 1992-10-16 1994-04-28 Stephen John Douglas Taste-masking compositions of ranitidine
US5505982A (en) * 1994-01-28 1996-04-09 Fmc Corporation Chocolate confection
NZ279954A (en) * 1994-02-04 1998-02-26 Scotia Lipidteknik Ab Lipophilic carrier preparation comprising a galacto-lipid material at least 50% of which comprises digalactosyldiacylglycerols
JP2948111B2 (ja) * 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物
DE29511421U1 (de) * 1995-07-14 1995-10-12 Chou, Wen San, An Ting, Tainan Luftkompressor
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
JP4449213B2 (ja) * 1997-10-08 2010-04-14 大正製薬株式会社 坐剤用組成物
GB9724544D0 (en) * 1997-11-21 1998-01-21 Smithkline Beecham Plc Novel Formulation
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
SE9804192D0 (sv) * 1998-12-03 1998-12-03 Scotia Lipidteknik Ab New formulation
EP1043016B1 (en) * 1999-03-30 2014-08-20 Sodic Sa A plant extract based on glycerides,phospholipids and phytosphingolipids, a method for the preparation of this extract and a cosmetic composition containing the same
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
MXPA03005169A (es) * 2000-12-14 2003-09-22 Hoffmann La Roche Matriz lipidica auto-emulsificante.

Also Published As

Publication number Publication date
ATE430585T1 (de) 2009-05-15
MXPA04007946A (es) 2005-06-08
PT1474174E (pt) 2009-06-25
EP1474174B1 (en) 2009-05-06
WO2003068267A1 (en) 2003-08-21
US20050181042A1 (en) 2005-08-18
DE60327511D1 (de) 2009-06-18
DK1474174T3 (da) 2009-07-06
RU2302260C2 (ru) 2007-07-10
JP2005520816A (ja) 2005-07-14
NZ534812A (en) 2006-10-27
SI1474174T1 (sl) 2009-08-31
AU2003206355B2 (en) 2007-03-01
CN101060862A (zh) 2007-10-24
CA2475025C (en) 2010-07-27
ES2324603T3 (es) 2009-08-11
EP1474174A1 (en) 2004-11-10
RU2004124042A (ru) 2005-06-10
CA2475025A1 (en) 2003-08-21
AU2003206355A1 (en) 2003-09-04
KR20040089633A (ko) 2004-10-21
ZA200406399B (en) 2005-09-12
SE0200475D0 (sv) 2002-02-15

Similar Documents

Publication Publication Date Title
JP6348942B2 (ja) 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
BR0313651A2 (pt) composiÇço para administraÇço oral ou rectal
PT797435E (pt) Matriz de libertacao controlada para produtos farmaceuticos
ME00416B (me) Celekoksibne smješe
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BR0317591A (pt) Composto, sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, métodos para tratar uma doença ou condição, para modular a função de crth2 e/ou um ou mais outros receptores de pgd2 em uma célula e para modular crth2 e/ou um ou mais outros receptores de pgd2
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
IL158899A0 (en) Pharmaceutical compositions for inhibiting angiogenesis containing oleuropein and derivatives thereof
MX2009005307A (es) Nuevas composiciones bajo la forma de ungüento libre de vaselina, que comprenden un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide.
AR055591A1 (es) Una composicion topica protectora de la piel y su uso
AR024240A1 (es) COMPUESTOS DE 4-(AMINOMETIL)-PIPERIDIN BENZAMIDA uTILES PARA TRATAR TRASTORNOS GASTROINTESTINALES, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE, PROCESO PARA PREPARAR DICHA COMPOSICIoN FARMACÉUTICA, COMPUESTO INTERMEDIARIO uTIL PARA PREPARA DICHOS COMPUESTOS DE BENZAMIDA, PROCESO PARA PREPARAR DICHOS
BR9914419A (pt) Terapia para melhoria da percepção
TW200603816A (en) Risedronate compositions and their methods of use
PT760668E (pt) Utilizacao de produto a base de magnesio para o tratamento ou profilaxia de doencas neoplasicas e auto-imunes
Zeitlin Can curcumin cure cystic fibrosis?
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
GB9809349D0 (en) Heterocyclic derivatives
UY25824A1 (es) Antagonista del receptor de vitronectina
BRPI0417123A (pt) formulação de torsemide de liberação prolongada
BRPI0410651A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
PL324012A1 (en) N-hydroxyureas as antiinflammatory agents
BR0004813A (pt) Constructos vesiculares marcados para citoproteção e tratamento de infecções por h. pylori
MY140954A (en) Composition for oral or rectal administration
BR0312778A (pt) Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: LTP LIPID TECHNOLOGIES PROVIDER AB (SE)

Free format text: AFIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020100032367/RJ DE 14/04/2010, E NECESSARIO APRESENTAR PROCURACAO OUTORGADA PELO CESSIONARIO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.

B25B Requested transfer of rights rejected

Owner name: LTP LIPID TECHNOLOGIES PROVIDER AB (SE)